Dictionary

allow_url_fopen is ENABLED Dictionary Search

factor ix

Synonyms

Noun

1. Christmas factor

2. factor IX, coagulation factor, clotting factor

Usage
Factor IX-Padua AAV gene therapy in hemophilia B: phases 1/2 and 3 trials - Nature
Single-Dose Gene Therapy Shows Promising Safety, Efficacy, and Patient-Reported Outcomes in Hemophilia B - Docwire News
Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B - NEJM
Angela Dugalic is UCLA’s X-factor - The IX Sports
EAHAD 2026: Nine-Year Outcomes of Gene Therapy - EMJ
Tailored collagen binding of albumin-fused hyperactive coagulation factor IX dictates in vivo distribution and functional properties - Nature
Explainer: Why Is Hemophilia B Called Christmas Disease? - Global Biotechnology Company
Advances in hemophilia, sickle cell disease, and thalassemia - Penn Medicine
Karmanos Cancer Institute Becomes First and Only Free-Standing Cancer Center to Treat Hemophilia B with New Gene Therapy - McLaren Health
Hemophilia B Gene Therapy Continues to Reduce Bleeding - Medscape
AAV gene therapy shows durable benefit in hemophilia B - 2 Minute Medicine
ASH: CSL proves efficacy of hemophilia B gene therapy Hemgenix holds up after 5 years - Fierce Pharma
New data suggest gene therapy may reach more hemophilia B patients - Hemophilia News Today
Exploring gene editing as a potential therapeutic strategy for hemophilia - Frontiers
Gene Therapy Maintains Efficacy in Hemophilia B Out to 5 Years - MedPage Today
Comparing Real-World Outcomes of Prophylaxis with Extended Half-life Factor IX (rIX-FP vs. rFIXFc and N9-GP) for Haemophilia B: An Analysis of Medical Chart Data from Germany - springermedicine.com
How Gene Therapy Is Transforming Hemophilia B Treatment - Docwire News
Eloctate, Alprolix control bleeds in hemophilia patients’ major surgeries - Hemophilia News Today
Optimization of hemophilia B treatment via population PK modeling of rIX-FP, including a 3-week regimen - Frontiers
How durable is gene therapy for haemophilia B? - Nature
Afghanistan Faces Shortage of Factor IX for 1,200 Hemophilia Patients - tolonews.com
First subject dosed in Be Biopharma’s trial of haemophilia B therapy - Clinical Trials Arena
Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant - NEJM
Coagulation factor IX analysis in bioreactor cell culture supernatant predicts quality of the purified product - Nature
The National “New Methods” Decision Forum in Norway recommends CSL’s gene therapy HEMGENIX® for adults with severe or moderately severe haemophilia B without a history of Factor IX inhibitors - Mynewsdesk
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B - NEJM
Successful management with regular factor IX replacement during pregnancy in a hemophilia B carrier: A case report - Wiley
Effects of codon optimization on coagulation factor IX translation and structure: Implications for protein and gene therapies - Nature
Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B - NEJM
Systemic delivery of factor IX messenger RNA for protein replacement therapy - PNAS
Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B - NEJM
A novel snake venom C-type lectin-like protein modulates blood coagulation by targeting von Willebrand factor and coagulation factor IX - Nature
Genome wide CRISPR/Cas9 screen identifies the coagulation factor IX (F9) as a regulator of senescence - Nature
Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec) Over Five Years - Mynewsdesk
X-Linked Thrombophilia with a Mutant Factor IX (Factor IX Padua) - NEJM
HTC Population Profile Patient Characteristics - Centers for Disease Control and Prevention | CDC (.gov)
Plasma factor IX: The tip of the iceberg? - Sidonio - 2021 - Haemophilia - Wiley Online Library
One dose of gene therapy gives years of relief from blood disorder - Nature
Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia B - NEJM
Plasma Kallikrein Contributes to Coagulation in the Absence of Factor XI by Activating Factor IX - American Heart Association Journals
Hemophilia B Gene Therapy Sustains Efficacy Over a Decade Later - MedPage Today
Hemophilia B gene therapy demonstrates long-term success - St. Jude Children's Research Hospital
Field Study Highlights Differences in Factor IX Variant Lab Results - AJMC
PBPK modeling of recombinant factor IX Fc fusion protein (rFIXFc) and rFIX to characterize the binding to type 4 collagen in the extravascular space - Wiley
CDC Hemophilia Mutation Projects (CHAMP and CHBMP) - Centers for Disease Control and Prevention | CDC (.gov)
First gene therapy to treat haemophilia B - European Medicines Agency (EMA)
Etranacogene Dezaparvovec Displays Superiority to Factor IX Prophylaxis for Hemophilia B in HOPE-B Trial Data - CGTLive®
Novel Insights and New Developments Regarding Coagulation Revealed by Studies of the Anti-Factor IXa (Activated Factor IX)/Factor X Bispecific Antibody, Emicizumab - American Heart Association Journals
Etranacogene Dezaparvovec Shows Durable Activity and Reduced Consumption of Factor IX in Hemophilia B After 3 Years - CGTLive®
A coagulation factor moonlights in the heart - Science | AAAS
This gene therapy costs $5 million a dose. Is it worth the price? - SMH.com.au
UC San Diego Health First to Offer Novel Gene Therapy for Hemophilia B - UC San Diego Health
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial - Applied Clinical Trials Online
Regeneron and Intellia Therapeutics Expand Collaboration to Develop CRISPR/Cas9-Based Treatments - Intellia Therapeutics
SRY-Box transcription factor 9 triggers YAP nuclear entry via direct interaction in tumors - Nature
Association Between Hepatic Triglyceride Content and Coagulation Factors: - American Heart Association Journals
AMT-061 Achieves Sufficient Increases in Factor IX Levels for Patients With Hemophilia B - AJMC
FDA Accepts Biogen Idec’s Biologics License Application for First Long-Lasting Factor IX Therapy for Hemophilia B - Biogen
Phase 1–2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B - NEJM
Intellia opts out of hemophilia B gene editing work with Regeneron - Fierce Biotech
Etranacogene dezaparvovec gene therapy reduces bleeding in severe hemophilia B - 2 Minute Medicine
Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B - NEJM
Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies - Wiley Online Library
Glucocorticoids increase adiposity by stimulating Krüppel-like factor 9 expression in macrophages - Nature
Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A - NEJM
Kallikrein directly interacts with and activates Factor IX, resulting in thrombin generation and fibrin formation independent of Factor XI - PNAS
Sustained correction of bleeding disorder in hemophilia B mice by gene therapy - PNAS
Press Release Service: Be Bio Announces New Preclinical Data Demonstrating its Novel Engineered B Cell Medicine (BCM), BE-101, Produces Active and Sustained Levels of Factor IX for the Treatment of Hemophilia B - CRISPR Medicine News
Pfizer: Beqvez Gene Therapy Decreases Bleeding Rates in Hemophilia B Patients - 2 Minute Medicine
Factor Levels Lower Than 50% Associated With Postpartum Complications in Patients With Hemophilia - Hematology Advisor
Krüppel-like factor 9 alleviates Alzheimer’s disease via IDE-mediated Aβ degradation - Nature
Hemophilia B Gene Therapy Produces Durable Response for 90% of Participants - AJMC
Evaluation of a New Concentrate for the Treatment of Factor IX Deficiency - NEJM
World Haemophilia Day on April 17 - Manorama Yearbook
Low-dose AAVS3 gene therapy is efficacious for treating patients with hemophilia B - 2 Minute Medicine
Coagulation factors VII, IX and X are effective antibacterial proteins against drug-resistant Gram-negative bacteria - Nature
Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response - Nature
Hemophilia B Gene Therapy Shows Promise as Long-Term Treatment - Docwire News
Personal Story: Carrie - Centers for Disease Control and Prevention | CDC (.gov)
Crystal structure of an anticoagulant protein in complex with the Gla domain of factor X - PNAS
Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector - Nature
Effective Blood Clotting Treatment:Pharmacogenomic Studies of ADAMTS13 - fda.gov
Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial - The Lancet
FDA Approves Second Gene Therapy for Hemophilia B - Medscape
A genetic analysis of 23 Chinese patients with hemophilia B - Nature
Haemophilia gene therapy patients thriving over a decade after treatment - UCL | University College London
ASH: CSL, uniQure's gene therapy Hemgenix shows durable protection in hemophilia B - Fierce Pharma
Hemophilia B Gene Therapy Shows Promise in Clinical Trial - Genetic Engineering and Biotechnology News
Emicizumab Prophylaxis in Hemophilia A with Inhibitors - NEJM
Hemophilia Gene Therapies Show Effectiveness and Safety in NEJM Reports - Inside Precision Medicine
The Prevalence of Proteolytic Antibodies against Factor VIII in Hemophilia A - NEJM
Fibroblast Growth Factor 9 is expressed by activated hepatic stellate cells and promotes progression of hepatocellular carcinoma - Nature
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors - NEJM
Is Hemophilia a Nosologic Entity? - ScienceDirect.com
Loss of Krüppel-like factor 9 deregulates both physiological gene expression and development - Nature
Phase III BENEGENE-2 Trial Shows Beqvez Significantly Reduces Bleeding in Hemophilia B - Applied Clinical Trials Online
Single-dose gene therapy is potentially life-changing for adults with hemophilia B - Penn Medicine
FDA OKs Second Gene Therapy for Hemophilia B - MedPage Today
Anticoagulant Protein S Targets the Factor IXa Heparin-Binding Exosite to Prevent Thrombosis - American Heart Association Journals
Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A - NEJM
Foreign Language Equivalents
Foreign Language Equivalents of 'factor ix'
Language Equivalent   Language Equivalent
French    Spanish
Misspellings - Typos
facror ix,   fator ix,   facttor ix,   facter ix,   factor iz,   factori x,   facctor ix,   afctor ix,   gactor ix,   actor ix,   factr ix,   dactor ix,   fatcor ix,   factor ox,   facor ix,   factor i,   faactor ix,   fsctor ix,   factot ix,   factor ix,   factir ix,   factro ix,   factor ixx,   facyor ix,   ffactor ix,   factorix,   factor ic,   factor iix,   factor x,   faxtor ix,   factoor ix,   fctor ix,   factor xi,   facotr ix,   fcator ix,   factor ux,   factoe ix,   facto ix,   factpr ix,   facto rix,   favtor ix,   factorr ix
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z